9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one

• ChemBase编号: 119255
• 分子式: C10H12N4O5
• 平均质量: 268.22608
• 单一同位素质量: 268.0807695
• SMILES: n1(c2c(nc1)c(=O)[nH]cn2)[C@H]1[C@@H]([C@@H]([C@H](O1)CO)O)O
• Canonical SMILES: OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1nc[nH]c2=O
• InChI: InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1
• InChIKey: UGQMRVRMYYASKQ-KQYNXXCUSA-N

名称和登记号

名称

• IUPAC标准名: 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one
• IUPAC传统名: 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one
• 别名: 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; Inosine; (-)-Inosine; Hypoxanthine 9-β-D-ribofuranoside; Inosine; Hypoxanthine riboside; Hypoxanthosine; Inosie; Oxiamine; Trophicardyl; Carnine

登记号

• CAS号: 58-63-9
• EC号: 200-390-4
• MDL号: MFCD00066770
• Beilstein号: 624896
• PubChem SID: 162102976; 24896051
• PubChem CID: 6021

理论计算性质

• Acid pKa: 8.933801
• 质子受体: 7
• 质子供体: 4
• LogD (pH = 5.5): -2.4786847
• LogD (pH = 7.4): -2.489615
• Log P: -2.478538
• 摩尔折射率: 61.3318 cm^3
• 极化性: 23.156597 Å^3
• 极化表面积: 129.2 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: H2O: soluble0.5 M, clear, colorless
• 熔点: 222-226 °C (dec.)(lit.)
• 比旋光度: [α]20/D -76±2°, c = 1% in 0.1 M NaOH

安全信息

• 德国WGK号: 2
• 个人保护装置: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter

药理学性质

• 作用靶点: Others
• 生物活性机理: Activates cellular functions by base pairs with Adenine HFN72-P, Cytosine HDR44-O or Uracil BTP40-U

产品相关信息

• 纯度: ≥99%; ≥99.0% (HPLC)
• 成盐信息: Free Base
• 燃烧残渣: ≤0.05%; ≤0.1%
• 杂质: ≤0.0005% Phosphorus (P); ≤0.2% Insoluble matter
• 痕量阳离子: Al: ≤0.0005%; Ca: ≤0.0005%; Cu: ≤0.0005%; Fe: ≤0.0005%; K: ≤0.005%; Mg: ≤0.0005%; Na: ≤0.005%; NH4+: ≤0.05%; Pb: ≤0.001%; Zn: ≤0.0005%
• 痕量阴离子: chloride (Cl-): ≤0.05%; sulfate (SO42-): ≤0.05%
• 生物来源: Prod. by microorganisms, e.g. Bacillus subtilis, E. coli, Saccharomyces cerevisiae, Fusarium spp.
• 应用领域: Cardiotonic; Used to treat cardiac disorders
• 品质说明: crystallized
• Empirical Formula (Hill Notation): C10H12N4O5

详细说明

Sigma Aldrich - I4125

包装
1, 5, 10, 25, 100 g in poly bottle
Biochem/physiol Actions
Inosine is a potent stimulator of nerve growth factor (NGF) induced neurite outgrowth. The elevated levels of inosine in brain following injury are associated with the increased expression proteins related to axonal regeneration and growth. Mice given inosine demonstrated enhanced recovery of fine motor control following ischemic brain damage. Inosine may be used in studies of the process A-to-I RNA editing.

Sigma Aldrich - I1024

Biochem/physiol Actions
Inosine is a potent stimulator of nerve growth factor (NGF) induced neurite outgrowth. The elevated levels of inosine in brain following injury are associated with the increased expression proteins related to axonal regeneration and growth. Mice given inosine demonstrated enhanced recovery of fine motor control following ischemic brain damage. Inosine may be used in studies of the process A-to-I RNA editing.

Sigma Aldrich - 57470

Biochem/physiol Actions
Inosine is a potent stimulator of nerve growth factor (NGF) induced neurite outgrowth. The elevated levels of inosine in brain following injury are associated with the increased expression proteins related to axonal regeneration and growth. Mice given inosine demonstrated enhanced recovery of fine motor control following ischemic brain damage. Inosine may be used in studies of the process A-to-I RNA editing.

参考文献

• Aldrich Library of FT-IR Spectra, 1st edn., 1985, 2, 712B, (ir)
• Aldrich Library of 13C and 1H FT NMR Spectra, 1992, 3, 215C, (nmr)
• Gulland, J.M. et al., J.C.S., 1936, 765, (struct)
• Hall, R.H., Biochem. Biophys. Res. Commun., 1963, 13, 394, (isol, deriv)
• Kinichi, I. et al., Chem. Pharm. Bull., 1966, 14, 1377, (synth)
• Japan. Pat., 1968, 68 13 215; CA, 70, 47808, (synth, isopropylidene)
• Munns, A.R.I. et al., Acta Cryst. B, 1970, 26, 1114, (cryst struct)
• Ger. Pat., 1972, 2038262; CA, 76, 99993e, (synth)
• Chenon, M.T. et al., J.A.C.S., 1975, 97, 4627, (cmr)
• Westhof, E. et al., Z. Naturforsch., C, 1975, 30, 131, (pmr)
• Hawkes, G.E. et al., J.C.S. Perkin 2, 1977, 1268, (N-15 nmr)
• Yamazaki, A. et al., J. Het. Chem., 1978, 15, 353, (rev, synth)
• Aviado, D.M., J. Pharmacol., 1983, 14, 47, (rev, pharmacol)
• Campoli-Richards, D.M. et al., Drugs, 1986, 32, 383, (rev, Inosine pranobex)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 1551
• De Simone, C. et al., Int. J. Immunopharmacol., 1991, 13, 19, (rev, Inosine pranobex)
• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 548; 1379
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, IDE000